Companies Dominating the Myxedema Coma Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Pfizer Inc.
- GSK plc.
- Sanofi Global
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lannett Company, Inc.
- Zydus Lifesciences
Browse Key Market Insights with Data Illustration:
In the News
- Mylan N.V received FDA approval for Ermeza (levothyroxine), which is available in oral dose formulations such as generic tablet and capsule forms, and can be used as a supplemental treatment to surgery and radioiodine therapy or as a replacement therapy for congenital or acquired hypothyroidism in adult and pediatric patients.
- Zydus Lifesciences got approval from the US Food and Drug Administration (USFDA) for marketing the Levothyroxine Sodium Injection which is used to treat myxedema coma or extreme hypothyroidism.